CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018. The management team will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m. ET to discuss the company's financial results and recent developments. The call can be accessed by dialing 1-844-784-1732 (domestic) or 1-412-902-6714 (international) five minutes prior to the start of the call. A passcode is not required to access the live call from either number. A replay of the conference call will be available until May 16, 2018 and can be accessed by dialing 1-412-317-0088 and providing the passcode 10119532.
The live, listen-only webcast of the conference call may be accessed by visiting the investors’ section of the company's website at investors.foundationmedicine.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website for two weeks following the call.
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180417005230/en/
Source: Foundation Medicine, Inc.